Scott C. Flanders

2.4k total citations
68 papers, 1.9k citations indexed

About

Scott C. Flanders is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Scott C. Flanders has authored 68 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Scott C. Flanders's work include Prostate Cancer Treatment and Research (43 papers), Prostate Cancer Diagnosis and Treatment (26 papers) and Radiopharmaceutical Chemistry and Applications (12 papers). Scott C. Flanders is often cited by papers focused on Prostate Cancer Treatment and Research (43 papers), Prostate Cancer Diagnosis and Treatment (26 papers) and Radiopharmaceutical Chemistry and Applications (12 papers). Scott C. Flanders collaborates with scholars based in United States, United Kingdom and Belgium. Scott C. Flanders's co-authors include Deborah P. Lubeck, James M. Henning, Mark S. Litwin, Gary D. Grossfeld, Peter R. Carroll, David J. Pasta, MARCIA L. STODDARD, JENNY YU, Jeanette M. Broering and David M. Stier and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Journal of Urology.

In The Last Decade

Scott C. Flanders

58 papers receiving 1.8k citations

Peers

Scott C. Flanders
Natalia Sadetsky United States
Florian R. Schroeck United States
Nikhil Shah United States
Per Fransson Sweden
Janeen DuChane United States
Arul Mahadevan United States
Xiao‐Cheng Wu United States
Gustavo Franco Carvalhal Brazil
Bridget F. Koontz United States
Lauren P. Wallner United States
Natalia Sadetsky United States
Scott C. Flanders
Citations per year, relative to Scott C. Flanders Scott C. Flanders (= 1×) peers Natalia Sadetsky

Countries citing papers authored by Scott C. Flanders

Since Specialization
Citations

This map shows the geographic impact of Scott C. Flanders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott C. Flanders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott C. Flanders more than expected).

Fields of papers citing papers by Scott C. Flanders

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott C. Flanders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott C. Flanders. The network helps show where Scott C. Flanders may publish in the future.

Co-authorship network of co-authors of Scott C. Flanders

This figure shows the co-authorship network connecting the top 25 collaborators of Scott C. Flanders. A scholar is included among the top collaborators of Scott C. Flanders based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott C. Flanders. Scott C. Flanders is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hafron, Jason, et al.. (2025). Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US. Future Oncology. 21(10). 1219–1230. 1 indexed citations
2.
Spratt, Daniel, Tanya B. Dorff, Rana R. McKay, et al.. (2024). Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol. Future Oncology. 20(12). 727–738. 3 indexed citations
3.
Sieber, Paul, et al.. (2024). Plain language review: the safety of relugolix combination therapy for advanced prostate cancer. Future Oncology. 21(1). 51–62.
4.
5.
Beebe‐Dimmer, Jennifer, Julie J. Ruterbusch, Lauren C. Bylsma, et al.. (2018). Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database. Advances in Therapy. 35(9). 1438–1451. 12 indexed citations
6.
Schultz, Neil M., Neal D. Shore, Simon Chowdhury, et al.. (2018). Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urology. 18(1). 77–77. 1 indexed citations
7.
Flanders, Scott C., Janet Kim, Samuel Wilson, et al.. (2018). Validating the Total Illness Burden Index for Prostate Cancer (TIBI-CaP) in Men with Castration-Resistant Prostate Cancer: Data from TRUMPET. Future Oncology. 14(6). 527–536.
8.
Nussbaum, Nathan C., Daniel J. George, Amy P. Abernethy, et al.. (2016). Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. Prostate Cancer and Prostatic Diseases. 19(2). 111–121. 56 indexed citations
9.
Penson, David F., Daniel W. Lin, Lawrence I. Karsh, et al.. (2016). Treatment Registry for Outcomes in Patients with Castration-Resistant Prostate Cancer (TRUMPET): A Methodology for Real-World Evidence and Research. Future Oncology. 12(23). 2689–2699. 5 indexed citations
10.
O’Day, Ken, Cat N. Bui, Scott C. Flanders, et al.. (2015). MP73-13 BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FROM A US PAYER PERSPECTIVE. The Journal of Urology. 193(4S). 1 indexed citations
11.
Fuller, Matthew A., Kenneth M. Shermock, Michelle Secic, et al.. (2009). Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. Journal of Medical Economics. 12(4). 317–324. 25 indexed citations
12.
Flanders, Scott C., Robert L. Findling, Eric A. Youngstrom, et al.. (2007). Observed Clinical and Health Services Outcomes in Pediatric Inpatients Treated with Atypical Antipsychotics: 1999–2003. Journal of Child and Adolescent Psychopharmacology. 17(3). 312–327. 3 indexed citations
13.
Flanders, Scott C., et al.. (2006). The economic burden of pervasive developmental disorders in a privately insured population.. PubMed. 19(8). 39–45. 9 indexed citations
14.
Litwin, Mark S., Deborah P. Lubeck, MARCIA L. STODDARD, et al.. (2001). Quality of Life Before Death for Men with Prostate Cancer. 1 indexed citations
15.
Grossfeld, Gary D., JAMES J. CHANG, Jeanette M. Broering, et al.. (2000). Does the completeness of prostate sampling predict outcome for patients undergoing radical prostatectomy?: data from the CaPSURE database. Urology. 56(3). 430–435. 35 indexed citations
16.
Litwin, Mark S., David J. Pasta, JENNY YU, MARCIA L. STODDARD, & Scott C. Flanders. (2000). URINARY FUNCTION AND BOTHER AFTER RADICAL PROSTATECTOMY OR RADIATION FOR PROSTATE CANCER:. The Journal of Urology. 1973–1977. 13 indexed citations
17.
Greenfield, Sheldon, et al.. (1999). Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology. 54(3). 424–429. 48 indexed citations
18.
Lubeck, Deborah P., et al.. (1999). Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE. Urology. 53(1). 180–186. 144 indexed citations
19.
Lubeck, Deborah P., David J. Pasta, Scott C. Flanders, & James M. Henning. (1999). Approaches to Missing Data Inference Results from CaPSURE. PharmacoEconomics. 15(2). 197–204. 5 indexed citations
20.
Litwin, Mark S., Scott C. Flanders, David J. Pasta, et al.. (1999). Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Urology. 54(3). 503–508. 237 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Natalia Sadetsky Breakdown of academic impact, for papers by Florian R. Schroeck Breakdown of academic impact, for papers by Nikhil Shah Breakdown of academic impact, for papers by Per Fransson Breakdown of academic impact, for papers by Janeen DuChane Breakdown of academic impact, for papers by Arul Mahadevan Breakdown of academic impact, for papers by Xiao‐Cheng Wu Breakdown of academic impact, for papers by Gustavo Franco Carvalhal Breakdown of academic impact, for papers by Bridget F. Koontz Breakdown of academic impact, for papers by Lauren P. Wallner
Rankless by CCL
2026